Oberweis Asset Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Oberweis Asset Management’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-33,300	Closed	-$388K	–	158
2013 Q3	$388K	Buy	+33,300	New	+$273K	0.11%	93

Other funds holding INSY

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Tamarack Capital Management Carlsbad, California $840M AUM 19.47% 1-Year Est. Return

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Oberweis Asset Management's INSY Position: Q4 2013 in Review

Oberweis Asset Management sold out of Insys Therapeutics, Inc. (INSY) in Q4 2013, closing a stake of 33,300 shares — an estimated $388K sold.

Oberweis Asset Management first reported a position in INSY in Q3 2013 and held it in 1 quarter. The position peaked at $388K in Q3 2013. 86 funds tracked by Wall St. Rank hold INSY as of Q4 2013.

Oberweis Asset Management reported no remaining Insys Therapeutics, Inc. position as of Q4 2013 after selling out during the quarter.
Oberweis Asset Management sold 33,300 Insys Therapeutics, Inc. shares in Q4 2013, an estimated $388K.
Oberweis Asset Management first reported a position in Insys Therapeutics, Inc. in Q3 2013 and held it in 1 quarter.
Oberweis Asset Management's Insys Therapeutics, Inc. position peaked at $388K in Q3 2013.
86 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2013.

Based on Oberweis Asset Management's 13F filing for Q4 2013, filed 14 Feb 2014.